^
Association details:
| Biomarker: | ERBB4 H809G + ER positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
Excerpt:
At the time of lapatinib resistance, the most abundant private mutation in plasma was in the tyrosine kinase domain of ERBB4 (p.H809G; plasma cluster 5; Fig. 2b,d and Supplementary Fig. 11).
DOI:
10.1038/ncomms9760
